The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of taxane versus TS-1 as first-line treatment for metastatic breast cancer (SELECT BC).
Fumikata Hara
Honoraria - Sanofi ; Taiho Pharmaceutical
Nobuaki Matsubara
No relevant relationships to disclose
Tsuyoshi Saito
No relevant relationships to disclose
Toshimi Takano
Honoraria - Bristol-Myers Squibb; Sanofi ; Taiho Pharmaceutical
Youngjin Park
No relevant relationships to disclose
Tatsuya Toyama
No relevant relationships to disclose
Yasuo Hozumi
Honoraria - Sanofi ; Taiho Pharmaceutical
Research Funding - Sanofi ; Taiho Pharmaceutical
Junji Tsurutani
No relevant relationships to disclose
Shigeru Imoto
No relevant relationships to disclose
Tsutomu Takashima
Honoraria - Taiho Pharmaceutical
Takanori Watanabe
No relevant relationships to disclose
Yoshiaki Sagara
No relevant relationships to disclose
Reiki Nishimura
Honoraria - Taiho Pharmaceutical
Yasuo Ohashi
Employment or Leadership Position - Statcom
Stock Ownership - Statcom
Honoraria - Chugai Pharma; Sanofi ; Shionogi
Research Funding - Astellas Pharma; Kyowa Hakko Kirin; Takeda
Hirofumi Mukai
Honoraria - Bristol-Myers Squibb; Sanofi ; Taiho Pharmaceutical